William Camu

William Camu

Professor of Neurology

Dr William Camu graduated as an MD and specialist in Neurology in 1989, at the Faculty of Medicine of Montpellier, France. He started his research on ALS in 1986 and has never given up to try to find a cure for ALS. In 1999 he became a Professor of Neurology at the Faculty and University hospitals of Montpellier. After he developed a method of purification for motoneuron cultures in the Christopher Henderson’s lab, he oriented his work on genetics with large and fruitful collaborations. The motoneuron team he is still heading, was labelled as a national expert ALS center in 2003. Prof. Camu is also heading the Clinical Neurophysiology department of the University Hospital Gui de Chauliac in Montpellier since 2005. His expertise covers clinical neurology, genetics, biomarkers and clinical research, including clinical trials. He has published more than 200 articles in referenced journals.

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more